Amneal Pharmaceuticals (AMRX) said Thursday that the Veterans Administration, UnitedHealthcare (UNH), and CVS Health (CVS) have added Parkinson's disease treatment Crexont to their national prescription drug formularies.
The company said the additional coverage increases the total US insurance coverage of Crexont to more than 50% of covered patients from about 30% at the end of 2024. Amneal added it had previously set a target of over 50% coverage by the end of 2025.
Price: 8.10, Change: -0.07, Percent Change: -0.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。